Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Antibody response against Mycobacterium avium complex in cystic fibrosis patients measured by a novel IgG ELISA test

Research output: Contribution to journalJournal articleResearchpeer-review

  1. In vivo demonstration of Pseudomonas aeruginosa biofilms as independent pharmacological microcompartments

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lung clearance index-triggered intervention in children with cystic fibrosis - A randomised pilot study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pseudomonas aeruginosa antibody response in cystic fibrosis decreases rapidly following lung transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The impact of chest computed tomography and chest radiography on clinical management of cystic fibrosis lung disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Pandemics: past, present, future: That is like choosing between cholera and plague

    Research output: Contribution to journalReviewResearchpeer-review

  2. Anti-biofilm Approach in Infective Endocarditis Exposes New Treatment Strategies for Improved Outcome

    Research output: Contribution to journalReviewResearchpeer-review

  3. Adjunctive S100A8/A9 Immunomodulation Hinders Ciprofloxacin Resistance in Pseudomonas aeruginosa in a Murine Biofilm Wound Model

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Omics-based tracking of Pseudomonas aeruginosa persistence in "eradicated" cystic fibrosis patients.

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Early signs of Mycobacterium avium complex pulmonary disease can be missed in patients with cystic fibrosis due to subclinical infection or delays in mycobacterial culture. The aim of this study was to determine the diagnostic accuracy of a novel enzyme linked immunosorbent assay for immunoglobulin G against Mycobacterium avium complex, which could help stratify patients according to risk.

METHODS: A retrospective cross sectional analysis of serum samples from the Copenhagen Cystic Fibrosis Center was performed. Corresponding clinical data were reviewed and patients with cystic fibrosis were assigned to one of four groups based on their mycobacterial culture results. In addition, anti-Mycobacterium avium complex immunoglobulin G levels were measured longitudinally before and after first positive culture in the period 1984-2015.

RESULTS: Three-hundred and five patients with cystic fibrosis were included with a median of five nontuberculous mycobacterial cultures. Four individuals had Mycobacterium avium complex pulmonary disease at the time of cross sectional testing and their median antibody level was 22-fold higher than patients with no history of infection (1820 vs. 80 IgG units; p < 0.001). Test sensitivity was 100% (95% CI 40-100) and specificity 77% (95% CI 72-81). Longitudinal kinetics showed rising antibodies prior to first positive culture suggesting diagnostic delay.

CONCLUSIONS: Antibody screening for Mycobacterium avium complex may be used as a supplement to culture. Although confirmation in a larger cohort is needed, our findings suggest that stratifying a cystic fibrosis population into high- and low-risk groups based on antibody levels may help clinicians identify patients in need of more frequent culture.

Original languageEnglish
JournalJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Volume18
Issue number4
Pages (from-to)516-521
Number of pages6
ISSN1569-1993
DOIs
Publication statusPublished - 2019

    Research areas

  • Accuracy, Diagnostic, Mycobacterium avium, Nontuberculous, Serology

ID: 56389866